| 摘要 |
<p>The invention relates to the use of glycoproteins extracted from the Klebsiella Pneumoniae bacterium for the production of a drug for the remedial treatment of acute or chronic infections. Said glycoproteins work by causing a quick lysis of all types of pathogens by means of very intense stimulation of all of the short-term, maximum 12 to 24 hour, anti-infective defence systems of the body. Said glycoproteins have proven the effectiveness thereof in 92% of common acute and chronic ORL infections, particularly in chronic otitis which, in the prior art, often progressed inevitably towards hearing loss. Said glycoproteins have proven the effectiveness thereof in many other infections in which the bacteria or viruses do not have a high pathogenicity.</p> |
